High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Significance: Nanoparticle-mediated delivery of siRNA to hepatocytes has treated disease in humans. However, systemically delivering RNA drugs to nonliver tissues remains an important challenge. To increase the number of nanoparticles that could be studied in vivo, we designed a high-throughput method to measure how >100 nanoparticles delivered mRNA that was translated into functional protein in vivo. We quantified how >250 lipid nanoparticles (LNPs) delivered mRNA in vivo, identifying two LNPs that deliver mRNA to endothelial cells. One of the LNPs codelivered Cas9 mRNA and single-guide RNA in vivo, leading to endothelial cell gene editing. This approach can identify nanoparticles that target new cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Such assemblies, complexed with polymers capable of disrupting endosomes and including DNA templates for homology-directed repair, were found to promote correction of dystrophin gene mutations in mice 80 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [80]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
A robust and high-throughput Cre reporting and characterization system for the whole mouse brain
Madisen, L., Zwingman, T. A., Sunkin, S. M., Oh, S. W., Zariwala, H. A., Gu, H., Ng, L. L., Palmiter, R. D., Hawrylycz, M. J., Jones, A. R., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2467 · Cited by 6,907
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390 · cited 1×
“To confirm protein silencing was mediated by gene editing, we measured (40) ICAM-2 insertions and deletions (indels) in lung, spleen, and kidney endothelial cells and found between 30 and 70% editing per locus, leading to overall ICAM-2 indel percentages of 135, 95, and 123% indel, respectively for 7C2 (Fig.”
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001 · cited 6×
“Next, C57BL/6J mice were injected two times with 2 mg/kg with 7C3 formulated to carry both SpCas9 mRNA (L-7206; Trilink Biotechnology) and e-sgICAM2 (AxoLabs) at a 1:1, 3:1, and 5:1 mass ratio.”
InfluentialSelf-citationRational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1×
“Moreover, LNP siRNA delivery is often tested in vivo using the FVII assay, which predicts hepatocyte delivery; this assay is enhanced by its ease, as well as the fact that validated, potent siRNA targeting FVII is available (18, 19).”
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460 · cited 1×
“In mice, nanoparticles have delivered Cas9 mRNA and ribonu-cleoproteins via systemic or local injection (5 – 12).”
Cited by
Items 301–312 of 312
Guérin, M., Saorin, A., & Martinez‐Serra, A. (2026) · Health Nanotechnology · doi:10.1186/s44301-026-00036-6 · Cited by 2
Review Article: mRNA CARs: An Emerging New-Old Idea
Wolf, Y. (2026) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2026066109
Yan, X., Ding, Z., & Yuan, P. (2026) · Nano Today · doi:10.1016/j.nantod.2026.103162
In vivo CAR‑T therapy: recent progress and future directions
Wang, W., Cai, Y., Yang, X., & Xu, H. (2026) · Immunity & Inflammation · doi:10.1007/s44466-026-00050-4
Petrova, E., Georgiev, I., Stoyanov, N., & Kolev, P. (2026) · Journal of Applied Pharmaceutical Technologies and Systems · doi:10.68159/a787099787
Beyond Precision: A Multidimensional Framework for Selecting Genetic Medicine Platforms
Wieland, J., Jackson, P., Penrod, W., Nadauld, S., & Barrott, J. J. (2026) · Cells · doi:10.3390/cells15181647
Multifunctional nucleic acid-based therapy in fibrosis-related diseases
Cheng, J., Zhou, M., Guo, Y., Yang, Y., Lv, W., Renzeng, Y. A. N. G., Xie, Y., Jiang, Y., Yao, L., Qi, C., et al. (2026) · Science China Chemistry · doi:10.1007/s11426-025-3231-6
Immune memory engineering in mRNA therapeutics
Wen, J., Tao, W., & Zhou, X. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115370
Li, K., Qi, H., 信瑶瑶, Qin, L., Cheng, Y., & Yao, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1930837
Xu, Z., Luo, X., Li, Y., Qian, J., & Xu, G. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1949512
High-Throughput Polymer Design for the Biological Interface
Chittari, S. S., & Gormley, A. J. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6c00447
Moovendhan, M. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.109068
Metadata
- Authors
- Sago, C. D., Lokugamage, M. P., Paunovska, K., Vanover, D. A., Monaco, C. M., Shah, N. N., Gamboa Castro, M., Anderson, S. E., Rudoltz, T. G., Lando, G. N., Munnilal Tiwari, P., Kirschman, J. L., Willett, N., Jang, Y. C., Santangelo, P. J., Bryksin, A. V., & Dahlman, J. E.
- Affiliations
- Georgia Institute of Technology (US)
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA 30332;
- Corresponding author
- Dahlman, James E.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2018-10
- Volume
- 115
- Issue
- 42
- Pages
- E9944-E9952
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6196543
- OpenAlex
- W2893976143
- Cited by
- 313
- References
- 45
- Citations by year
- 2026: 37 · 2025: 45 · 2024: 46 · 2023: 44 · 2022: 58 · 2021: 31 · 2020: 36 · 2019: 16
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-11-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- HHS | National Institutes of Health (T32EB021962, T32GM008433, 5T32EB006343)
- Cystic Fibrosis Foundation (DAHLMA15XX0)
- Parkinson's Disease Foundation (PDF-JFA-1860)
- Bayer (AGE DTD)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- lipid nanoparticles, mRNA delivery, endothelial cells, CRISPR/Cas9 genome editing, siRNA delivery, single guide RNA, hepatocytes
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Animals, Cells, Cultured, Humans, Lipids, Mice, Inbred C57BL, RNA, Messenger, Gene Transfer Techniques, Hepatocytes, Endothelial Cells, Mice, Nanoparticles, High-Throughput Screening Assays, HEK293 Cells, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.